Fonte: BMC Pharmacology. Nome do evento: International Conference on cGMP: Generators, Effectors and Therapeutic Implications. Unidade: ICB
Assunto: FARMACOLOGIA
ABNT
DE NUCCI, Gilberto et al. Pharmacological characterization of the novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. BMC Pharmacology. London: Instituto de Ciências Biomédicas, Universidade de São Paulo. . Acesso em: 01 nov. 2024. , 2007APA
De Nucci, G., Lorenzetti, R., Okuyama, C. E., Baracat, J. S., Donato, J. L., Antunes, E., & Teixeira, C. E. (2007). Pharmacological characterization of the novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. BMC Pharmacology. London: Instituto de Ciências Biomédicas, Universidade de São Paulo.NLM
De Nucci G, Lorenzetti R, Okuyama CE, Baracat JS, Donato JL, Antunes E, Teixeira CE. Pharmacological characterization of the novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. BMC Pharmacology. 2007 ; 7[citado 2024 nov. 01 ]Vancouver
De Nucci G, Lorenzetti R, Okuyama CE, Baracat JS, Donato JL, Antunes E, Teixeira CE. Pharmacological characterization of the novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. BMC Pharmacology. 2007 ; 7[citado 2024 nov. 01 ]